Drugs / LOXO-783
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06102512 | Oct → Dec 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06028425 | Sep → Dec 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05894928 | Jun → Jul 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05307705 | May 2022 → Dec 2026 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOXO-783 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06102512 ↗ |
| Route | Oral | “LOXO-783 administered orally” NCT05307705 ↗ |